T. Fr.J



MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

> DIRECT DIAL: TELEPHONE:

(512) 536-3035

FACSIMILE:

(512) 474-5201 (512) 536-4598

November 30, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on t

November 30, 2004

Date

Mark B. Wilson

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RE: U.S. Patent Application No. 10/786,875 entitled "IMPROVED NUCLEASE INHIBITOR

COCKTAIL" – Gary J. Latham et al.

Our reference: AMBI:089US

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A2, B1, and C1-C27.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:089US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark B. Wilson Reg. No. 37,259

MBW/kmv Encl.: as noted





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary J. Latham et al.

Serial No.: 10/786,875

Filed: February 25, 2004

For: IMPROVED NUCLEASE INHIBITOR

COCKTAIL

Group Art Unit: 1634

Examiner: Unknown

Atty. Dkt. No.: AMBI:089US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:

November 30, 2004

Date

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/AMBI:089US.

This application is related by subject matter to co-pending U.S. application number

09/669,301 filed September 25, 2000 now issued as 6,664,379, number 10/675,860 filed

September 30, 2003, and provisional application number 60/547,721 filed February 25, 2004.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Mark B. Wilson

Reg. No. 37,259

FULBRIGHT & JAWORSKI L.L.P. Attorney for Applicants 600 Congress Avenue, Suite 2400

Austin, Texas 78701

(512) 474-5201

Date:

November 30, 2004

25477153.1

Form PTO-1449 (modified)

Atty. Docket No.
AMBI:089US

Serial No. 10/786,875

List of Patents and Publications for Applicant's

Applicant
Gary J. Latham et al.

Information Disclosure Statement

(Use several sheets if necessary)

Filing Date: February 25, 2004 Group: 1634

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	Al	6,110,968	8/29/00	Bucala et al.	514	482	11/10/98
	A2	6,664,379	12/16/03	Kudlicki et al.	530	387.9	9/25/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 2004/005663	1/15/04	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation				
-	C1	Allewell and Sama, "The effect of ammonium sulfate on the activity of ribonuclease a," Biochem. Biophys. ACTA, 341:484-488, 1974.				
	C2	Blackburn et al., "Ribonuclease inhibitor from human placenta: interaction with derivatives of ribonuclease A," J. Biol. Chem. 252:12488-12493, 1977.				
	C3	Blumberg, "Creating a ribonuclease-free environment," Methods Enzymol. 152:20-24, 1987.				
	C4	Cazenave, "Idiotypic-anti-idiotypic regulation of antibody synthesis in rabbits," <i>Proc. Natl. Acad. Sci. USA</i> , 74:5122-5125, 1977.				
	C5	Chirgwin, et al., "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> 18:5294-5299, 1979.				
	C6	Chomczynski and Sacchi, "Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction," <i>Anal. Biochem.</i> 162:156-159, 1987.				
	C7	Chomczynski, "Solubilization in formamide protects RNA from degradation," <i>Nucleic Acids Res.</i> 20:3791-3792, 1992.				
	C8	Coburn and Mackie, "Overexpression, purification, and properties of Escherichia coli ribonuclease II," J. Biol. Chem. 271:1048-1053, 1996.				
	C9	Gilleland and Hockett Jr., "Stability of RNA molecules stored in gitc," <i>Biotechniques</i> 25:944-948, 1998.				

25462392.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. AMBI:089US	Serial No. 10/786,875
List of Patents and Publications for	Applicant's	Applicant Gary J. Latham <i>et al.</i>	
Information Disclosure St	TATEMENT		
(Use several sheets if necessar	ry)	Filing Date: February 25, 2004	Group: 1634
U.S. Patent Documents	Foreign Patent Documents		Other Art
See Page 1	S	ee Page 1	See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Jocoli and Ronald, "Inhibition of ribonuclease activity by bentonite," Can. J. Biochem. 51:1558-1565, 1973.
	C11	Jones, "On the efficacy of commonly used ribonuclease inhibitors," <i>Biochem. Biophys. Res. Commun.</i> 69:469-474, 1976.
-	C12	Lee et al., "The use of immobilized anti-ribonuclease antibodies in the isolation of polyribosomes," <i>Immunochemistry</i> , 9:210-213, 1972.
	C13	Lin, "Inactivation of pancreatic ribonuclease with hydroxylamine-oxygen-cupric ion," <i>Biochim. et Biophys. Acta</i> 263:680-682, 1972.
	C14	Mendelsohn and Young, "Efficacy of sodium dodecyl sulfate, diethyl pyrocarbonate, proteinase k and heparin using a sensitive ribonuclease assay," <i>Biochim. et Biophys. Acta</i> 519:461-473, 1978.
	C15	Murphy et al., "A potent, cost-effective RNase inhibitor," Biotechniques 18:1068-1073, 1995.
	C16	O'Leary, "Reducing the Impact of Endogenous Ribonucleases on Reverse Transcription-PCR Assay Systems," Clinical Chemistry, 45(4):449-450, 1999.
	C17	Pelham and Jackson, "An efficient mRNA dependent translation system for reticulocyte lysates," Eur. J. Biochem. 67:247-256, 1976.
	C18	Russo and Shapiro, "Potent inhibition of mammalian ribonucleases by 3' 5'-pyrophosphate-linked nucleotides," <i>J. Biol. Chem.</i> 274:14,902-14,908, 1999.
	C19	Sambrook, et al., "Molecular cloning, a laboratory manual," pp. 7.16-7.52, 1989.
	C20	Spackman et al., "The Disulfide Bonds of Ribonuclease," J. Biol. Chem. 235:648-659, 1960.
	C21	Spickler and Mackie, "Action of RNase ii and polynucleotide phosphorylase against RNase containing stem-loops of defined structure," <i>J. Bacteriology</i> 182(9): 2422-2427, 2000.
	C22	Trent et al., "A comparison of new world alphaviruses in the western equine encephalomyelitis complex by immunochemical and oligonucleotide fingerprint techniques," J. Gen. Virol., 47:261-282, 1980.
	C23	Wolf et al., "A mechanism of the irreversible inactivation of bovine pancreatic ribonuclease by diethylpyrocarbonate," Eur. J. Biochem. 13:519-525, 1970.
	C24	Wu, et al., "Methods in Gene Biotechnology," CRC Press, Boca Raton, FL, pp. 29-56, 1997.

25462392.1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. AMBI:089US	Serial No. 10/786,875
List of Patents and Publications for	Applicant's	Applicant Gary J. Latham et al.	
Information Disclosure St	ATEMENT		
(Use several sheets if necessar	у)	Filing Date: February 25, 2004	Group: 1634
U.S. Patent Documents	Foreign P	atent Documents	Other Art
See Page 1	See Page 1 See Page 1 S		See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
	C25	Zale and Klibanov, "Why does ribonuclease irreversibly inactivate at high temperatures?," <i>Biochemistry</i> 25:5432-5444, 1986.		
	C26	Provisional Application Number 60/547,721 filed February 25, 2004.		
	C27	Co-Pending U.S. Patent Application Number 10/675,860 filed September 30, 2003.		

25462392.1

Examiner: Date Considered:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.